Message #7 From:
Stock News Bot Date: November 3, 2005 10:27:00 AM
ADXS News Advaxis to Present at the Rodman and Renshaw Techvest 7th Annual Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Nov. 3, 2005--Advaxis, Inc. (OTCBB: ADXS), a developer of Listeria monocytogenes based cancer vaccines, will be presenting at the Rodman and Renshaw Techvest 7th Annual Health Care Conference on Tuesday November 8, 2005 at 3:50 PM. The conference is being held in New York City at The Palace Hotel, 455 Madison Avenue, from November 7-9, 2005.
The presentation will be given by the Advaxis management team, which includes: J. Todd Derbin, CEO, Roni Appel, CFO, and Dr. John Rothman, VP of Clinical Development. The presentation will provide an overview of the Company and will focus on its cancer products, current drug pipeline, and new developments.
About Advaxis
Advaxis is based in Princeton, New Jersey. Advaxis is developing proprietary Listeria cancer vaccines based on the vaccine technology developed by Dr. Yvonne Paterson in the Department of Microbiology at the University of Pennsylvania. Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities. Advaxis, through its proprietary Listeria monocytogenes based system, is utilizing two immunological mechanisms (Innate and Classical Immunity) to develop safer and more effective Listeria based cancer vaccines. Advaxis is the exclusive licensee of a patented broadly enabling Listeria platform technology based on the use of attenuated bacteria Listeria monocytogenes that can elicit effective anti-tumor responses. Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets cervical and head and neck cancers. Further Listeria vaccines in development target breast, ovarian and lung cancers. Advaxis is entering a Phase I/II clinical trial in late 2005. The Listeria platform will also have applications in the fields of infectious disease and autoimmune disorders.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
